Detalles de la búsqueda
1.
The cost-effectiveness of isavuconazole compared to voriconazole, the standard of care in the treatment of patients with invasive mould diseases, prior to differential pathogen diagnosis in Spain.
Mycoses
; 64(1): 66-77, 2021 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-32989796
2.
Economic evaluation of azoles as primary prophylaxis for the prevention of invasive fungal infections in Spanish patients undergoing allogeneic haematopoietic stem cell transplant.
Mycoses
; 60(2): 79-88, 2017 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-27562016
3.
Economic and Humanistic Burden of Moderate and Severe Hemophilia A and B in Spain: Real-World Evidence Insights from the CHESS II Study.
J Health Econ Outcomes Res
; 11(1): 122-133, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38721331
4.
Real-World Health Care Outcomes and Costs Among Patients With Juvenile Idiopathic Arthritis in Spain.
J Health Econ Outcomes Res
; 10(2): 141-149, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-38145114
5.
Ceftaroline Fosamil for the Empiric Treatment of Hospitalized Adults with cSSTI: An Economic Analysis from the Perspective of the Spanish National Health System.
Clinicoecon Outcomes Res
; 14: 149-161, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35330907
6.
Cost-effectiveness analysis of using innovative therapies for the management of moderate-to-severe ulcerative colitis in Spain.
Expert Rev Pharmacoecon Outcomes Res
; 22(1): 73-83, 2022 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-33615953
7.
Cost of patients with hemophilia A treated with standard half-life or extended half-life FVIII in Spain.
Expert Rev Pharmacoecon Outcomes Res
; 21(2): 315-320, 2021 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-32597317
8.
Health and economic impact of the correct diagnosis of transthyretin cardiac amyloidosis in Spain.
Expert Rev Pharmacoecon Outcomes Res
; 21(5): 1127-1133, 2021 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-34047214
9.
Estimating the annual economic burden for the management of patients with transthyretin amyloid polyneuropathy in Spain.
Expert Rev Pharmacoecon Outcomes Res
; 21(5): 967-973, 2021 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-33724140
10.
Cost-effectiveness analysis of second-line pharmacological treatment of acromegaly in Spain.
Expert Rev Pharmacoecon Outcomes Res
; 20(1): 105-114, 2020 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-31055976
11.
Economic analysis of ceftaroline fosamil for treating community-acquired pneumonia in Spain.
J Med Econ
; 23(2): 148-155, 2020 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-31686550
12.
Burden of diabetes mellitus in patients with acromegaly treated with second-line pharmacotherapy in Spain.
Clinicoecon Outcomes Res
; 11: 465-475, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31413609
13.
Economic Impact of Etanercept in Patients with Psoriasis and Psoriatic Arthritis in Spain: A Systematic Review.
Dermatol Ther (Heidelb)
; 9(3): 479-496, 2019 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-31062222
14.
Cost-effectiveness analysis of combination antifungal therapy with voriconazole and anidulafungin versus voriconazole monotherapy for primary treatment of invasive aspergillosis in Spain.
Clinicoecon Outcomes Res
; 9: 39-47, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-28115858
15.
Cost-effectiveness analysis of fesoterodine flexible dose in newly diagnosed patients with overactive bladder in routine clinical practice in Spain.
Clinicoecon Outcomes Res
; 8: 541-550, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-27713646
16.
Cost Analysis of the Use of Voriconazole, Posaconazole and Micafungin in the Primary Prophylaxis of Invasive Fungal Infections in Recipients of Allogeneic Hematopoietic Stem Cell Transplants.
J Health Econ Outcomes Res
; 3(2): 153-161, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-35619591
17.
Anaphylaxis caused by cloxacillin: diagnosis with seriated analysis by way of basophil activation test.
Allergy Asthma Proc
; 27(3): 269-72, 2006.
Artículo
en Inglés
| MEDLINE | ID: mdl-16913272
Resultados
1 -
17
de 17
1
Próxima >
>>